Business
BillionToOne is a molecular diagnostics company built around a single-molecule next-generation sequencing platform and Quantitative Counting Templates.
BillionToOne nearly doubled revenue and turned profitable, with positive FCF and a broad insider purchase cluster.
The read at a glance✓ Audited against SEC data
- Business mix — Molecular diagnosticsNote
- Revenue — Revenue up 100.0%OK
- Income — Net income $7.5MOK
- FCF — FCF swung to $15.7MOK
- Equity — Equity rose to $480.1MOK
- Insiders — 6 purchases / 0 salesOK
- Accounting — Altman-Z grey; Beneish clean; EQ safeNote
Where the revenue comes from
Fiscal 2025, as BillionToOne, Inc. reports it. History and quarterly detail are in the app.
- Prenatal$277.1M
- Oncology$25.0M
- Clinical trial support and other services$3.1M
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-06-29
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BillionToOne, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.